Targeting DNA topoisomerase II in cancer chemotherapy

被引:1362
|
作者
Nitiss, John L. [1 ]
机构
[1] St Jude Childrens Res Hosp, Dept Med Pharmacol, Memphis, TN 38105 USA
关键词
DOUBLE-STRAND BREAKS; DEPENDENT PROTEIN-KINASE; ACUTE MYELOID-LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; END-JOINING PATHWAYS; RECEPTOR-ALPHA GENES; SACCHAROMYCES-CEREVISIAE; COVALENT COMPLEXES; CELL-CYCLE; HOMOLOGOUS RECOMBINATION;
D O I
10.1038/nrc2607
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent molecular studies have expanded the biological contexts in which topoisomerase 11 (TOP2) has crucial functions, including DNA replication, transcription and chromosome segregation. Although the biological functions of TOP2 are important for ensuring genomic integrity, the ability to interfere with TOP2 and generate enzyme-mediated DNA damage is an effective strategy for cancer chemotherapy. The molecular tools that have allowed an understanding of the biological functions of TOP2 are also being applied to understanding the details of drug action. These studies promise refined targeting of TOP2 as an effective anticancer strategy.
引用
收藏
页码:338 / 350
页数:13
相关论文
共 50 条
  • [21] Targeting topoisomerase II with the chiral DNA-intercalating ruthenium(II) polypyridyl complexes
    Feng Gao
    Hui Chao
    Jin-Quan Wang
    Yi-Xian Yuan
    Bin Sun
    Yuan-Fang Wei
    Bin Peng
    Liang-Nian Ji
    JBIC Journal of Biological Inorganic Chemistry, 2007, 12 : 1015 - 1027
  • [22] Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy
    Ali, Yousaf
    Abd Hamid, Shafida
    TUMOR BIOLOGY, 2016, 37 (01) : 47 - 55
  • [23] DNA topoisomerase IIα and -β expression in human ovarian cancer
    S Withoff
    A G J van der Zee
    S de Jong
    H Hollema
    E F Smit
    N H Mulder
    E G E de Vries
    British Journal of Cancer, 1999, 79 : 748 - 753
  • [24] DNA topoisomerase IIα and -β expression in human ovarian cancer
    Withoff, S
    van der Zee, AGJ
    de Jong, S
    Hollema, H
    Smit, EF
    Mulder, NH
    de Vries, EGE
    BRITISH JOURNAL OF CANCER, 1999, 79 (5-6) : 748 - 753
  • [25] Contemporary Challenges in the Design of Topoisomerase II Inhibitors for Cancer Chemotherapy
    Bailly, Christian
    CHEMICAL REVIEWS, 2012, 112 (07) : 3611 - 3640
  • [26] Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
    O'Malley, F. P.
    Chia, S.
    Tu, D.
    Shepherd, L. E.
    Levine, M. N.
    Bramwell, V. H.
    Andrulis, I. L.
    Pritchard, K. I.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (09): : 644 - 650
  • [27] Inhibition of DNA topoisomerase II with etoposide induces association of DNA topoisomerase IIα, DNA topoisomerase IIβ, and nucleolin with BCR 2 of the ETO gene
    Rubtsov, M. A.
    Razin, S. V.
    Iarovaia, O. V.
    DOKLADY BIOCHEMISTRY AND BIOPHYSICS, 2008, 423 (01) : 334 - 336
  • [28] Inhibition of DNA topoisomerase II with etoposide induces association of DNA topoisomerase IIα, DNA topoisomerase IIβ, and nucleolin with BCR 2 of the ETO gene
    M. A. Rubtsov
    S. V. Razin
    O. V. Iarovaia
    Doklady Biochemistry and Biophysics, 2008, 423 : 334 - 336
  • [29] Targeting DNA topoisomerase IIα activity with thiomaltol-based organometallic complexes
    Novak, M.
    Hackl, C.
    Kandioller, W.
    Jakupec, M.
    Keppler, B.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S73 - S73
  • [30] A CARBOLINE DERIVATIVE AS A NOVEL MAMMALIAN DNA TOPOISOMERASE-II TARGETING AGENT
    POGNAN, F
    SAUCIER, JM
    PAOLETTI, C
    KACZMAREK, L
    NANTKANAMIRSKI, P
    MORDARSKI, M
    PECZYNSKACZOCH, W
    BIOCHEMICAL PHARMACOLOGY, 1992, 44 (11) : 2149 - 2155